concanamycin A

Modify Date: 2024-01-03 22:34:16

concanamycin A structure	Common Name	concanamycin A
	CAS Number	80890-47-7	Molecular Weight	866.09
	Density	1.2±0.1 g/cm3	Boiling Point	966.4±65.0 °C at 760 mmHg
	Molecular Formula	C₄₆H₇₅NO₁₄	Melting Point	179-180℃ (dichloromethane ethanol )
	MSDS	Chinese USA	Flash Point	538.3±34.3 °C
	Symbol	GHS06	Signal Word	Danger

Use of concanamycin A

Concanamycin A (Antibiotic X 4357B; Concanamycin; X 4357B) is a macrolide antibiotic and a specific vacuolar type H+-ATPase (V-ATPase) inhibitor[1].

Name	concanamycin A
Synonym	More Synonyms

Description	Concanamycin A (Antibiotic X 4357B; Concanamycin; X 4357B) is a macrolide antibiotic and a specific vacuolar type H+-ATPase (V-ATPase) inhibitor[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump
Target	Vacuolar type H+-ATPase[1]
References	[1]. Togashi K, et al. Concanamycin A, a vacuolar type H(+)-ATPase inhibitor, induces cell death in activated CD8(+) CTL. Cytotechnology. 1997 Nov;25(1-3):127-35. [2]. Eswarappa SM, et al. Folimycin (concanamycin A) inhibits LPS-induced nitric oxide production and reduces surface localization of TLR4 in murine macrophages. Innate Immun. 2008 Feb;14(1):13-24.

Density	1.2±0.1 g/cm3
Boiling Point	966.4±65.0 °C at 760 mmHg
Melting Point	179-180℃ (dichloromethane ethanol )
Molecular Formula	C₄₆H₇₅NO₁₄
Molecular Weight	866.09
Flash Point	538.3±34.3 °C
Exact Mass	865.518738
PSA	225.92000
LogP	3.88
Vapour Pressure	0.0±0.6 mmHg at 25°C
Index of Refraction	1.555
Storage condition	−20°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CB9732000

CHEMICAL NAME :: Antibiotic X 4357 B

CAS REGISTRY NUMBER :: 80890-47-7

LAST UPDATED :: 199712

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C46-H75-N-O14

MOLECULAR WEIGHT :: 866.22

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 21 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4076802

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2450 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4076802

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H300 + H310 + H330-H319
Precautionary Statements	P260-P264-P280-P284-P301 + P310-P302 + P350
Personal Protective Equipment	Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes	T+
Risk Phrases	26/27/28-36
Safety Phrases	26-36/37/39-45
RIDADR	UN 3462 6.1/PG 2
WGK Germany	3
RTECS	CB9732000
Packaging Group	III
Hazard Class	6.1(b)

2,4-Dichlorophenoxyacetic acid alters intracellular pH and ion transport in the outer mantle epithelium of the bivalve Anodonta cygnea.

Aquat. Toxicol. 154 , 12-8, (2014)

Bivalve molluscs, due to their sedentary mode of life and filter-feeding behavior, are very susceptible to pollutant bioaccumulation and used as sentinel organisms in the assessment of environment pol...

Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion.

Int. J. Cancer 132(2) , E1-10, (2013)

Vacuolar ATPases (V-ATPases) comprise specialized and ubiquitously distributed pumps that acidify intracellular compartments and energize membranes. To gain new insights into the roles of V-ATPases in...

Functional characterization of the Plasmodium falciparum chloroquine-resistance transporter (PfCRT) in transformed Dictyostelium discoideum vesicles.

PLoS ONE 7(6) , e39569, (2012)

Chloroquine (CQ)-resistant Plasmodium falciparum malaria has been a global health catastrophe, yet much about the CQ resistance (CQR) mechanism remains unclear. Hallmarks of the CQR phenotype include ...

antibioticx4357b

S-45A

MFCD00210037

Antibiotic A661I

(5R)-3-O-(4-O-Carbamoyl-2,6-dideoxy-β-D-arabino-hexopyranosyl)-2,4-dideoxy-1-C-{(2S,3R,4S)-4-[(2R,3S,4E,6E,9R,10S,11S,12R,13R,14E,16Z)-11-ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxooxacyclooctadeca-4,6,14,16-tetraen-2-yl]-3-hydroxypentan-2-yl}-4-methyl-5-[(1E)-prop-1-en-1-yl]-α-D-threo-pentopyranose

FOLIMYCIN,STREPTOMYCES SP

α-D-threo-Pentopyranose, 3-O-[4-O-(aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]-2,4-dideoxy-1-C-[(1S,2R,3S)-3-[(2R,3S,4E,6E,9R,10S,11S,12R,13R,14E,16Z)-11-ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxooxacyclooctadeca-4,6,14,16-tetraen-2-yl]-2-hydroxy-1-methylbutyl]-4-methyl-5-C-[(1E)-1-propen-1-yl]-, (5R)-

A661-I

FOLIMYCIN

Antibiotic S-45A

x4357b

α-D-threo-Pentopyranose, 3-O-[4-O-(aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]-2,4-dideoxy-1-C-[(1S,2R,3S)-3-[(2R,3S,4E,6E,9R,10S,11S,12R,13R,14E,16Z)-11-ethyl-10,12-dihydroxy-3,17-di methoxy-7,9,13,15-tetramethyl-18-oxooxacyclooctadeca-4,6,14,16-tetraen-2-yl]-2-hydroxy-1-methylbutyl]-4-methyl-5-C-[(1E)-1-propen-1-yl]-, (5R)-

Concanamycin A,(3Z,5E,7R,8R,9S,10S,11R,13E,15E,17S,18R)-18-[(1S,2R,3S)-3-[(2R,4R,5S,6R)-4-[[4-O-(Aminocarbonyl)-2,6-dideoxy-β-D-arabino-hexopyranosyl]oxy]tetrahydro-2-hydroxy-5-methyl-6-(1E)-1-propenyl-2H-pyran-2-yl]-2-hydroxy-1-methylbutyl]-9-ethyl-8,10-

CONCANAMYCIN A

(5R)-3-O-(4-O-Carbamoyl-2,6-dideoxy-β-D-arabino-hexopyranosyl)-2,4-dideoxy-1-C-{(2S,3R,4S)-4-[(2R,3S,4E,6E,9R,10S,11S,12R,13R,14E,16Z)-11-ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl- 18-oxooxacyclooctadeca-4,6,14,16-tetraen-2-yl]-3-hydroxy-2-pentanyl}-4-methyl-5-[(1E)-1-propen-1-yl]-α-D-threo-pentopyranose